Soframycin
Manufactured By Sanofi India Limited
Composition Framycetin Sulphate 1% W/W + Methyl Paraben 0.08% W/W + Propyl Paraben 0.04% W/W
RS 48.23
MRP RS 56.74
(15% OFF)
Includes all taxes
Package SIZE
( 1 Cream )
100% Authentic
Products
Free
Shipping*
Products
Return Policy
Description:
Soframycin Skin Cream is used for Bacterial infections in skin lesions, Bacterial infection of the eye or ear, Otitis externa caused by susceptible bacteria, Superficial eye infections caused by susceptible bacteria and other conditions.Soframycin Skin Creammay also be used for purposes not listed in this medication guide.Soframycin Skin Creamcontains Framycetin Topical as an Active ingredient.
Soframycin Skin Creamworks by inhibiting the translation during protein synthesis of bacteria.
Uses / Indications:
Soframycin Skin Cream is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:
Bacterial infections in skin lesions
Bacterial infection of the eye or ear
Otitis externa caused by susceptible bacteria
Superficial eye infections caused by susceptible bacteria
Interactions / Warnings:
Do not take Soframycin Skin Cream 100 gm if you are allergic to Soframycin Skin Cream 100 gm, antibiotics related to aminoglycosides, suffering from a disorder called myasthenia gravis (severe weakness of muscles in the body), and dehydration. Talk to your doctor before taking Soframycin Skin Cream 100 gm if you have hearing problems such as tinnitus (buzzing or ringing in the ears), kidney problems. Do not use Soframycin Skin Cream 100 gm in your ear if you have a hole in your eardrum. If you are pregnant or breast-feeding, talk to your doctor before taking Soframycin Skin Cream 100 gm. The doctor will prescribe you Soframycin Skin Cream 100 gm only if the benefits outweigh the potential risks.
Prolonged local use leads to skin sensitisation and possible cross-sensitivity to other aminoglycosides. Hypersensitivity reactions may occur during local treatment. Topical use in perforated tympanic membranes may result in deafness. Aminoglycoside antibiotics may cause irreversible, partial or total deafness when given systemically or when applied topically to open wounds or damaged skin. This effect is dose-related and is enhanced by renal or hepatic impairment. Although this effect has not been reported in topical treatment, the possibility should be considered when high dose topical treatment is given to small children or infants.